Liquid Biopsies Treating Ovarian Cancer
News Jul 22, 2016
Researchers at the Mayo Clinic Center for Individualized Medicine have found a promising new way to monitor and treat recurrence of ovarian cancer — a hard-to-detect disease that claims many lives. New research from George Vasmatzis, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, finds liquid biopsies from blood tests and DNA sequencing can detect a return of ovarian cancer long before a tumour reappears. That could lead to earlier intervention and more effective, individualized treatment. Dr. Vasmatzis’ research on the “Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-free DNA from Ovarian Cancers” is published in the July 20 edition of Scientific Reports.
“With liquid biopsies, we don’t have to wait for tumour growth to get a DNA sample,” says Dr. Vasmatzis. “This important discovery makes it possible for us to detect recurrence of the disease earlier than other diagnostic methods. We can repeat liquid biopsies to monitor the progression of the cancer. That gives hope of a better treatment plan over time.”
The study was done on 10 patients in advanced stages of ovarian cancer. Blood was drawn before and after surgery. Investigators compared DNA from the liquid blood biopsies to DNA tissue samples from the tumour, using mate-pair sequencing — an inexpensive whole exome sequencing that can reveal genetic changes that contribute to tumour growth.
“In this study, the blood drawn before and after surgery and the surgical tissue was used to identify DNA fragments with abnormal junctions that can only be seen in this patient’s tumour DNA,” explains Dr. Vasmatzis. “Next-generation mate-pair sequencing was used to identify specific DNA changes of the tumour to create an individualized monitoring panel for liquid biopsy. This allows us to shape treatment to the individual patient rather than using a standard treatment that may not work for everyone.”
When post-surgery DNA matched that of the tumour, patients were later found to have had a recurrence of ovarian cancer. However, when the post-surgery DNA did not match the DNA of the tumour, patients were found to be in remission.
Ovarian cancer has one of the highest death rates of all gynecological cancers, because the tumour often cannot be detected until the late stages. Most patients go into remission after initial treatment, but the tumour returns 75 percent of the time. The next stage of ovarian cancer that develops typically does not respond to chemotherapy. More than 21,000 women in the U.S. were diagnosed with ovarian cancer, and 14,000 women died of the disease in 2015.
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Understanding the Process of Cell DivisionNews
Using multiple techniques such as structural modelling, X-ray scattering, X-ray crystallography and electron microscopy, scientists have found that the Spc110 protein provides a greater function in mitosis originally believed. This information could help understand the process in human cells and the abnormalities that occur in cancer.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018